arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

SCYNEXIS INC

SCYX
$4.66 ▼ -0.18 (-3.72%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
55 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
21
Health
Poor
Bearish
auto_awesome

Analytical Summary

SCYNEXIS INC faces fundamental challenges with weakness in Profit Margin (%) and Operating Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $55.1M
Dividend Yield
Revenue Growth -82.8%
Op. Margin None
ROIC -9.2%
FCF / Share $-1.26
Trailing P/E 7.4x
Price / Book 5.5x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Sep 23, 2026.

55-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$235.00K
↓ -82.8%
Net Income Profit after all expenses
$7.40M
↑ +134.7%
Operating Margin Operating profit as % of sales
56.4%
↑ +114.2% 3th
FCF / Share Free cash flow per share
$-1.26
↑ +1.0%
Long-Term Debt Long-term obligations
$34.65M
↑ +1.4%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability
6
Returns
29
Financial Health
19
Cash Quality
45

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 14 years · 55 quarters